EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction

European Urology

Volumn 56, Issue 1, 2009, Pages 81-88

  Stöhrer, Manfred ^a   Blok, Bertil ^b   Castro Diaz, David ^c   Chartier Kastler, Emanuel ^d   Del Popolo, Giulio ^e   Kramer, Guus ^f   Pannek, Jürgen ^g   Radziszewski, Piotr ^h   Wyndaele, Jean Jacques ⁱ  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f Bennebroek ^*  (Netherlands)

^g SWISS PARAPLEGIC RESEARCH   (Switzerland)

^h MEDICAL UNIVERSITY OF WARSAW   (Poland)

ⁱ ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

EAU guideline; Follow up; Incontinence; Quality of life; Urodynamics; Voiding dysfunction

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CAPSAICIN; DARIFENACIN; FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PROPIVERINE; PROSTATE SPECIFIC ANTIGEN; RESINIFERATOXIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

AUTONOMIC DYSREFLEXIA; BLADDER CATHETERIZATION; BLADDER EMPTYING; BLADDER NECK STENOSIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG MEGADOSE; ELECTROMYOGRAPHY; HUMAN; IDIOPATHIC DISEASE; INDWELLING CATHETER; INTENSIVE CARE; LIFE EXPECTANCY; LOWER URINARY TRACT SYMPTOM; MUSCLE WEAKNESS; NEUROGENIC BLADDER; NEUROGENIC LOWER URINARY TRACT SYMPTOM; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPHYSIOLOGY; OVERACTIVE BLADDER; PATHOGENESIS; PATIENT ASSESSMENT; PATIENT INFORMATION; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RESIDUAL URINE; REVIEW; RISK FACTOR; SPHINCTEROTOMY; ULTRASOUND; UNSPECIFIED SIDE EFFECT; URINARY TRACT; URODYNAMICS;

DIAGNOSIS, DIFFERENTIAL; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; UROLOGIC DISEASES;

EID: 67349117295     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.04.028     Document Type: Review

References (55)

1. Lapides J., Diokno A.C., Silber S.J., and Lowe B.S. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol 107 (1972) 458-461
2. Hackler R.H. A 25-year prospective mortality study in the spinal cord injured patient: comparison with the long-term living paraplegic. J Urol 117 (1977) 486-488
3. Stöhrer M, Castro-Diaz D, Chartier-Kastler E, et al. EAU guidelines on neurogenic urinary tract dysfunction. Paper presented at: the 23rd Annual Congress of the European Association of Urology; March 26-29, 2008, Milan, Italy.
4. Levels of evidence. Centre for Evidence Based Medicine Web site. http://www.cebm.net/index.aspx?o=1025. Accessed February 2009.
5. Stohrer M., Goepel M., Kondo A., et al. The standardization of terminology in neurogenic lower urinary tract dysfunction with suggestions for diagnostic procedures. Neurourol Urodyn 18 (1999) 139-158
6. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
7. Madersbacher H. The various types of neurogenic bladder dysfunction: an update of current therapeutic concepts. Paraplegia 28 (1990) 217-229
8. Satar N., Bauer S.B., Shefner J., Kelly M.D., and Darbey M.M. The effects of delayed diagnosis and treatment in patients with an occult spinal dysraphism. J Urol 154 (1995) 754-758
9. Watanabe T., Vaccaro A.R., Kumon H., Welch W.C., Rivas D.A., and Chancellor M.B. High incidence of occult neurogenic bladder dysfunction in neurologically intact patients with thoracolumbar spinal injuries. J Urol 159 (1998) 965-968
10. Bemelmans B.L., Hommes O.R., Van Kerrebroeck P.E., Lemmens W.A., Doesburg W.H., and Debruyne F.M. Evidence for early lower urinary tract dysfunction in clinically silent multiple sclerosis. J Urol 145 (1991) 1219-1224
11. Ahlberg J., Edlund C., Wikkelso C., Rosengren L., and Fall M. Neurological signs are common in patients with urodynamically verified "idiopathic" bladder overactivity. Neurourol Urodyn 21 (2002) 65-70
12. Yokoyama T., Nozaki K., Nose H., Inoue M., Nishiyama Y., and Kumon H. Tolerability and morbidity of urodynamic testing: a questionnaire-based study. Urology 66 (2005) 74-76
13. Wyndaele J.J., Castro D., Madersbacher H., et al. Neurologic urinary and fecal incontinence. In: Abrams P., Cardozo L., Khoury S., and Wein A. (Eds). Incontinence Vol. 2 (2005), Health Publications, Plymouth, UK 1059-1062
14. Chancellor M.B., Anderson R.U., and Boone T.B. Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 85 (2006) 536-545
15. Stöhrer M., Mürtz G., Kramer G., Schnabel F., Arnold E.P., Wyndaele J.J., and Propiverine Investigator Group. Propiverine compared to oxybutynin in neurogenic detrusor overactivity - results of a randomized, double-blind, multicenter clinical study. Eur Urol 51 (2007) 235-242
16. Buyse G., Waldeck K., Verpoorten C., Bjork H., Casaer P., and Andersson K.E. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 160 (1998) 892-896
17. Guttmann L., and Frankel H. The value of intermittent catheterisation in the early management of traumatic paraplegia and tetraplegia. Paraplegia 4 (1966) 63-84
18. Wyndaele J.J. Intermittent catheterization: which is the optimal technique?. Spinal Cord 440 (2002) 432-437
19. Hudson E., and Murahata R.I. The "no-touch" method of intermittent urinary catheter insertion: can it reduce the risk of bacteria entering the bladder?. Spinal Cord 43 (2005) 611-614
20. Wyndaele J.J. Complications of intermittent catheterization: their prevention and treatment. Spinal Cord 40 (2002) 536-541
21. Chao R., Clowers D., and Mayo M.E. Fate of upper urinary tracts in patients with indwelling catheters after spinal cord injury. Urology 42 (1993) 259-262
22. West D.A., Cummings J.M., Longo W.E., Virgo K.S., Johnson F.E., and Parra R.O. Role of chronic catheterization in the development of bladder cancer in patients with spinal cord injury. Urology 53 (1999) 292-297
23. Mitsui T., Minami K., Furuno T., Morita H., and Koyanagi T. Is suprapubic cystostomy an optimal urinary management in high quadriplegics? A comparative study of suprapubic cystostomy and clean intermittent catheterization. Eur Urol 38 (2000) 434-438
24. Talja M., Korpela A., and Järvi K. Comparison of urethral reaction to full silicone, hydrogen-coated and siliconised latex catheters. Br J Urol 66 (1990) 652-657
25. McClurg D., Ashe R.G., Marshall K., and Lowe-Strong A.S. Comparison of pelvic floor muscle training,electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study. Neurourol Urodyn 25 (2006) 337-348
26. Moore K.N., Schieman S., Ackerman T., Dzus H.Y., Metcalfe J.B., and Voaklander D.C. Assessing comfort, safety, and patient satisfaction with three commonly used penile compression devices. Urology 63 (2004) 150-154
27. Stohrer M., Schurch B., Kramer G., Schmid D., Gaul G., and Hauri D. Botulinum-A toxin in the treatment of detrusor hyperreflexia in spinal cord injury: a new alternative to medical and surgical procedures?. Neurourol Urodyn 18 (1999) 401-402
28. Del Popolo G., Filocamo M.T., Li Marzi V., et al. Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur Urol 53 (2008) 1013-1020
29. Schurch B., de Sèze M., Denys P., et al., Botox Detrusor Hyperreflexia Study Team. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo-controlled 6-month study. J Urol 174 (2005) 196-200
30. Ehren I., Volz D., Farrelly E., et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 41 (2007) 335-340
31. Grosse J., Kramer G., and Stöhrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47 (2005) 653-659
32. Haferkamp A., Schurch B., Reitz A., et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 46 (2004) 784-791
33. Cruz F., and Dinis P. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. Neurourol Urodyn 26 Suppl (2007) 920-927
34. MacDonald R., Monga M., Fink H.A., and Wilt T.J. Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. J Spinal Cord Med 31 (2008) 157-165
35. Reynard J.M., Vass J., Sullivan M.E., and Mamas M. Sphincterotomy and the treatment of detrusor-sphincter dyssynergia: current status, future prospects. Spinal Cord 41 (2003) 1-11
36. Dykstra D.D., and Sidi A.A. Related treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 71 (1990) 24-26
37. Wilson T.S., Lemack G.E., and Dmochowski R.R. UroLume stents: lessons learned. J Urol 167 (2002) 2477-2480
38. Block C.A., Cooper C.S., and Hawtrey C.E. Long-term efficacy of periurethral collagen injection for the treatment of urinary incontinence secondary to myelomeningocele. J Urol 169 (2003) 327-329
39. Granata C., Buffa P., Di Rovasenda E., et al. Treatment of vesico-ureteric reflux in children with neuropathic bladder: a comparison of surgical and endoscopic correction. J Pediatr Surg 34 (1999) 1836-1838
40. Ponce Díaz-Reixa J., Sánchez Rodríguez-Losada J., Alvarez Castelo L., et al. Vesicoureteral reflux in spinal cord injured patients. Treatment results and statistical analysis [in Spanish]. Actas Urol Esp 31 (2007) 366-371
41. Chartier-Kastler E.J., Mongiat-Artus P., Bitker M.O., Chancellor M.B., Richard F., and Denys P. Long-term results of augmentation cystoplasty in spinal cord injury patients. Spinal Cord 38 (2000) 490-494
42. Stöhrer M., and Pannek J. Surgery to improve reservoir function. In: Corcos J., and Schick E. (Eds). Textbook of the Neurogenic Bladder. 2nd ed. (2008), Informa Healthcare, London, UK 634-641
43. Stöhrer M., Kramer G., Goepel M., Lochner-Ernst D., Kruse D., and Rubben H. Bladder autoaugmentation in adult patients with neurogenic voiding dysfunction. Spinal Cord 35 (1997) 456-462
44. Kutzenberger J. Surgical therapy of neurogenic detrusor overactivity (hyperreflexia) in paraplegic patients by sacral deafferentation and implant driven micturition by sacral anterior root stimulation: methods, indications, results, complications, and future prospects. Acta Neurochir Suppl 97 (2007) 333-339
45. Wallace P.A., Lane F.L., and Noblett K.L. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 197 (2007) 96 e1-5
46. Stein R., Fisch M., Ermert A., et al. Urinary diversion and orthotopic bladder substitution in children and young adults with neurogenic bladder: a safe option for treatment?. J Urol 163 (2000) 568-573
47. Schwartz S.L., Kennelly M.J., McGuire E.J., and Faerber G.J. Incontinent ileo-vesicostomy urinary diversion in the treatment of lower urinary tract dysfunction. J Urol 152 (1994) 99-102
48. Lai H.H., Hsu E.I., Teh B.S., Butler E.B., and Boone T.B. 13 years of experience with artificial urinary sphincter implantation at Baylor College of Medicine. J Urol 177 (2007) 1021-1025
49. Herschorn S., and Radomski S.B. Fascial slings and bladder neck tapering in the treatment of male neurogenic incontinence. J Urol 147 (1992) 1073-1075
50. Hamid R., Khastgir J., Arya M., Patel H.R., and Shah P.J. Experience of tension-free vaginal tape for the treatment of stress incontinence in females with neuropathic bladders. Spinal Cord 41 (2003) 118-121
51. Patki P., Woodhouse J.B., Patil K., Hamid R., and Shah J. An effective day case treatment combination for refractory neuropathic mixed incontinence. Int Braz J Urol 34 (2008) 63-71 discussion 71-2
52. Catto J.W., Natarajan V., and Tophill P.R. Simultaneous augmentation cystoplasty is associated with earlier rather than increased artificial urinary sphincter infection. J Urol 173 (2005) 1237-1241
53. Ku J.H. The management of neurogenic bladder and quality of life in spinal cord injury. BJU Int 98 (2006) 739-745
54. Bonniaud V., Jackowski D., Parratte B., et al. Quality of life in multiple sclerosis patients with urinary disorders: discriminative validation of the English version of Qualiveen. Qual Life Res 14 (2005) 425-431
55. Kalsi V., Apostolidis A., Popat R., Gonzales G., Fowler C.J., and Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49 (2006) 528-535